Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PSIGBearishLegalnews

High materiality7/10

PSIG faces Nasdaq MVLS deficiency; 180-day window to cure listing risk

Aug 14, 2026, 4:29 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory delisting risk creates liquidity concerns and potential dilution if capital actions are pursued; small-cap stocks often suffer meaningful price downside on MVLS deficiency announcements. The 180-day window is a finite catalyst for remedial actions and investor scrutiny.

AI summary

What happened, with direct paths to the underlying reporting

PS International Group disclosed a Nasdaq deficiency letter indicating MVLS fell below the US$35 million threshold, triggering a 180-day cure period to Feb. 8, 2027. To regain full listing, PSIG must close above $35 million MVLS for ten consecutive trading days; failure could lead to formal delisting. There is no immediate suspension, but liquidity and capital-formation risks may weigh on the stock.

Nasdaq issues MVLS deficiency for PSIG. 180-day cure window ends Feb 8, 2027.
To regain listing, PSIG must close MVLS at $35m for 10 days.
No immediate suspension; shares continue on Nasdaq Capital Market.
Company may appeal; management monitoring MVLS and other strategic options.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.